DIFFUSION PHARMACEUTICALS IN (DFFN)
US2537484048 - Common Stock
3.86 -0.14 (-3.5%)
After market: 3.9 +0.04 (+1.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages DFFN, KMF, CSTI, and BGRY Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Diffusion to merge with EIP Pharma in all-stock deal
Diffusion Pharmaceuticals (DFFN) is merging with privately held EIP Pharma in an all-stock deal to focus on neuro diseases. Read more here
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in...
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at...
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate,...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly...
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when...
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities...
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022...
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting...
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.• No Change to Meeting Location, Record Date, or Proposals to Be...
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO TrialPhase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to...